Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical indication for cardioversion of AF~* Current episode of symptomatic AF lasting between 3-hour and 7 days (inclusive) at randomization~* Adequate anticoagulation according to international and/or national guidelines~Key Exclusion Criteria:~* Significant clinical illness or surgical procedure within 4 weeks preceding the screening visit~* History of significant mental, renal or hepatic disorder, chronic obstructive pulmonary disease, sinus nodal disease, or other significant disease, as judged by the investigator.~* Any cardioversion attempt of AF or atrial flutter within 4 weeks preceding randomization~* Use of any antiarrhythmic drug class I and/or III within 6 months before randomisation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: AP30663 (Type: EXPERIMENTAL): Participants will receive single dose of AP30663.
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to AP30663.
- Part 2: AP30663 (Type: EXPERIMENTAL): Participants will receive a single dose of one of the multiple dose levels of AP30663.
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched to AP30663.

Based on this trial design, predict the completion outcome and termination type (if applicable).